类风湿关节炎合并淋巴瘤:法国病例对照研究
该法国多中心病例对照研究纳入54例类风湿关节炎(RA)后发生B细胞非霍奇金淋巴瘤或霍奇金淋巴瘤的患者,与108例ESPOIR队列对照按年龄匹配。淋巴瘤以弥漫大B细胞淋巴瘤(DLBCL)为主(50.0%)。单变量分析显示男性、ACPA阳性、类风湿因子阳性、影像学骨侵蚀及DAS28与淋巴瘤发生相关,而甲氨蝶呤、TNF抑制剂及既往生物制剂数量无关联;多变量分析中骨侵蚀和DAS28仍显著相关。
要点
- RA合并淋巴瘤以DLBCL为主,占50.0%。
- 骨侵蚀和DAS28是淋巴瘤发生的独立危险因素。
- 甲氨蝶呤和TNF抑制剂未显示与淋巴瘤发生相关。
核心结论
- RA患者淋巴瘤风险随疾病活动度和严重度标志物升高而增加,支持自身免疫与淋巴瘤发生连续体的假说。
研究设计与样本
- 法国多中心病例对照研究,54例RA后发生B细胞非霍奇金淋巴瘤或霍奇金淋巴瘤的患者与108例ESPOIR队列对照按年龄1:2随机匹配。
主要发现
- 淋巴瘤以DLBCL为主(n=27,50.0%),27例免疫组化中4例(14.8%)EB病毒阳性。
- 单变量分析中,男性(OR 3.3,95%CI 1.7至6.7)、ACPA阳性(OR 5.1,95%CI 2.0至15.7)、类风湿因子阳性(OR 3.9,95%CI 1.6至12.2)、影像学骨侵蚀(OR 3.8,95%CI 1.7至8.3)及匹配时DAS28(OR 2.0,95%CI 1.5至2.7)与淋巴瘤发生相关。
- 甲氨蝶呤、TNF抑制剂及既往生物制剂数量与淋巴瘤发生无关联。
- 多变量分析中骨侵蚀和DAS28仍与淋巴瘤风险增加显著相关。
关键数值与推荐
- 病例需符合ACR-EULAR 2010标准诊断RA,且在RA诊断后发生B细胞非霍奇金淋巴瘤或霍奇金淋巴瘤。
临床怎么用
- 对RA患者应积极控制疾病活动度并监测骨侵蚀,以可能降低淋巴瘤风险。
- 甲氨蝶呤或TNF抑制剂使用史不应作为淋巴瘤风险的独立顾虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study the characteristics of B-cell non-Hodgkin's lymphoma (NHL) or Hodgkin lymphoma complicating rheumatoid arthritis (RA) and to identify RA-related factors associated with their occurrence. METHODS: A multicentre case-control study was performed in France. Cases were patients with RA fulfilling ACR-EULAR 2010 criteria in whom B-cell NHL or Hodgkin lymphoma developed after the diagnosis of RA. For each case, 2 controls were assigned at random from the ESPOIR cohort and were matched on age at lymphoma diagnosis (cases)/age at the 10-year follow-up visit in the cohort (controls). Case and control characteristics were compared to identify parameters associated with the occurrence of lymphoma. RESULTS: 54 cases were included and matched to 108 controls. Lymphomas were mostly diffuse large B-cell lymphoma (DLBCL, n=27, 50.0%). On immunochemistry, 4 of 27 (14.8%) lymphoma cases were positive for Epstein-Barr virus. On univariate analysis, factors associated with the occurrence of lymphoma were male sex (OR 3.3, 95% CI 1.7 to 6.7), positivity for ACPA (OR 5.1, 95% CI 2.0 to 15.7) and rheumatoid factor (OR 3.9, 95% CI 1.6 to 12.2), and erosions on radiographs (OR 3.8, 95% CI 1.7 to 8.3) and DAS28 (OR 2.0, 95% CI 1.5 to 2.7), both at the time of matching. Methotrexate, TNF blockers and a number of previous biologics were not associated with the occurrence of lymphoma. On multivariable analysis, erosions and DAS28 remained significantly associated with increased risk of lymphoma. CONCLUSION: Lymphomas complicating RA are mostly DLBCL. Risk of lymphoma in patients with RA was increased with markers of disease activity and severity, which supports the paradigm of a continuum between autoimmunity and lymphomagenesis in RA.
引用
- Kedra J, Seror R, Dieudé P, et al. Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open. 2021. PMID: 34470830. doi:10.1136/rmdopen-2021-001698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。